New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
Authors
Keywords
-
Journal
HEPATOLOGY RESEARCH
Volume 45, Issue 10, Pages E1-E11
Publisher
Wiley
Online
2014-12-05
DOI
10.1111/hepr.12459
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- (2017) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib
- (2014) Noriyuki Koyama et al. BMC CANCER
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
- (2014) Masatoshi Kudo et al. HEPATOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Mutational landscape of HCC—the end of the beginning
- (2014) Augusto Villanueva et al. Nature Reviews Clinical Oncology
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
- (2013) Kaoru Tsuchiya et al. CANCER
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
- (2013) Xiao-Yong Huang et al. HEPATOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
- (2013) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
- (2012) S Hagiwara et al. BRITISH JOURNAL OF CANCER
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
- (2012) Hashem B. El-Serag GASTROENTEROLOGY
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
- (2012) Tokuzo Arao et al. HEPATOLOGY
- Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
- (2012) Shunsuke Kondo et al. International Journal of Clinical Oncology
- Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma
- (2012) Beom Kyung Kim et al. LIVER INTERNATIONAL
- Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
- (2012) Cécile Guichard et al. NATURE GENETICS
- Liver Resection and Transplantation in Hepatocellular Carcinoma
- (2012) J. Belghiti et al. Liver Cancer
- The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
- (2011) Weon-Kyoo You et al. BMB Reports
- A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
- (2011) Stephen L. Chan et al. CANCER
- Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma
- (2011) Kazuomi Ueshima et al. DIGESTIVE DISEASES
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
- (2011) Koji Miyahara et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
- (2011) A. A. Adjei et al. ONCOLOGIST
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2011) T. Yau et al. ONCOLOGIST
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
- (2010) Fumihiko Kanai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting the HGF/c-Met Axis: State of Play
- (2010) T. A. Yap et al. MOLECULAR CANCER THERAPEUTICS
- The role of signaling pathways in the development and treatment of hepatocellular carcinoma
- (2010) S Whittaker et al. ONCOGENE
- Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
- (2009) S J Schoenleber et al. BRITISH JOURNAL OF CANCER
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Angiogenesis in liver disease
- (2009) Mercedes Fernández et al. JOURNAL OF HEPATOLOGY
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Novel advancements in the management of hepatocellular carcinoma in 2008
- (2008) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
- (2008) Mariona Graupera et al. NATURE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
- (2007) Klaus Juergen Schmitz et al. JOURNAL OF HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now